The DUPLEX® Premium Drug Delivery System is now available to meet hospital needs for delivery of antibiotic therapy.
Bethlehem (U.S.A.). B. Braun Medical Inc., announced the recent U. S. Food and Drug Administration (FDA) approval of CeFOXItin for injection in the DUPLEX® Drug Delivery System. DUPLEX is now the only ready-to-use IV drug delivery system available for CeFOXItin therapy in the United States.
"DUPLEX provides hospitals with a premium drug delivery system for CeFOXItin, allowing continued use of this effective antibiotic therapy despite recent market changes," said Rick Williamson, Director of Marketing, Drug Delivery, B. Braun Medical Inc. "Ensuring a safe and easy-to-use drug delivery system for CeFOXItin remains available to hospitals nationwide reflects our commitment to customers and patients – we provide innovative solutions for pharmacists and nurses that reduce labor costs and improve patient safety."
The DUPLEX system is designed to alleviate pharmacist and caregiver workload while protecting patients from potential medication errors. DUPLEX helps clinicians comply with Joint Commission on Accreditation of Healthcare Organizations (JCAHO) and USP <797> Guidelines that specify medicines should be dispensed in their "most ready-to-use form." The system is also equipped with a unique barcode system that references the final admixture and can be used to reduce medication errors, automate patient charting, track inventory and facilitate reimbursement tracking.
"The self-contained, ready-to-use formula saves valuable time by eliminating the need for mixing vials or thawing a frozen solution," said James Abberton, M.S., R.Ph., Director of Pharmacy, Long Island Jewish Medical Center, New York. "Our nursing staff has also found DUPLEX to be a well-organized and intuitive system that is simple to use, which therefore enhances patient safety by reducing the potential for medication dosing errors."
In light of Baxter Healthcare´s discontinuation of frozen Mefoxin® (cefoxitin for injection), B. Braun is currently accepting calls to assist customers affected by the anticipated supply shortage. B. Braun can be reached at 1-800-BBRAUN-2 (800-227-2862). With the addition of CeFOXItin to its drug delivery portfolio, B. Braun now offers a broad spectrum of intravenous cephalosporin antibiotic therapies for the hospital setting, covering the first three generations of cephalosporins: Cefazolin, CeFOXItin, CefuROXIme and CefTRIaxONE. CeFOXItin in the DUPLEX Drug Delivery System will be available in July 2006.
About DUPLEX
The DUPLEX Drug Delivery System is a closed system that ensures sterility and dose accuracy. It consists of a pre-filled, latex- and PVC/DEHP-free IV bag containing accurate doses of drug and diluent in different compartments, separated by a quick release seal. There are no vials to attach or activate, and there is no possibility of delivering the diluent without the drug. Prior to activation, it can be stored at room temperature for up to 18 months and does not require a thawing process.
